The Fda part is interesting considering if it's 10 percent improvement upon soc how is it that fast track is not warranted when you are talking about in the neighborhood of 160,000 plus or minus new cases a year. Then extrapolate that on Multikine for the potential of other cancers. Now those other cancers are delayed on a life saving/prolonging treatment. So really it's screwing alot more than the head and neck cancer etc. To go on from that it makes you wonder how the fda views Multikine.
If we had reached the 10 percent improvement on soc we would be way way above this market value. Head and neck cancer alone is around 4 billion gross alone assume 160,000 patients and $25,000 at least for Multikine. I don't even know if it's $25k for the 3 weeks of Multikine or that's $25k each injection. I assume we aren't there yet...
Did you include Indeed, patients who dropped out ? Something not to forget if you want study to be realistic Feel free to play with my model here and give me the output. I am particularily interested in cancer survival figures you might compute.
Market Data 
Markets 
AI
